<DOC>
	<DOCNO>NCT00000891</DOCNO>
	<brief_summary>To evaluate relationship viral suppression change immune function , measure restoration delayed-type hypersensitivity ( DTH ) lymphoproliferative ( LP ) responses , observe 48 week treatment highly active antiretroviral therapy ( HAART ) ACTG 315 . To evaluate durability antiviral immunologic effect long-term treatment HAART . Given extensive immunologic virologic data available ACTG 315 , follow-up study advanced-disease population indicate primarily ascertain impact long-term suppression viral replication immunologic reconstitution re-education durability antiviral effect HAART .</brief_summary>
	<brief_title>Immunologic Virologic Consequences Long-Term Highly Active Antiretroviral Therapy ( HAART ) Subjects With Moderately Advanced HIV-1 Disease : A Follow-Up Study ACTG 315</brief_title>
	<detailed_description>Given extensive immunologic virologic data available ACTG 315 , follow-up study advanced-disease population indicate primarily ascertain impact long-term suppression viral replication immunologic reconstitution re-education durability antiviral effect HAART . Patients continue current ACTG 315 regimen zidovudine plus lamivudine plus ritonavir open-label fashion undergo 6 week extensive evaluation . Treatment decision base baseline viral load ( mean 2 viral load measurement take 6-week evaluation ) . Patients HIV-1 RNA le 100 copies/ml continue ACTG 315 regimen . Patients HIV-1 RNA 100-3000 copies/ml may continue ACTG 315 regimen initiate new HAART regimen select local investigator primary care physician . Patients HIV-1 RNA great 3000 copies/ml initiate new HAART regimen select local investigator primary care physician . [ AS PER AMENDMENT 4/10/00 : Changes regimens must do consultation study team . The team acknowledge viable regimen may available give patient plasma HIV RNA level 3,000 copies/ml . In case , patient may remain fail regimen evaluation every 8 week viable regimen become available . ] All patient require maintain HAART regimen contain least 3 drug , 1 protease inhibitor . [ AS PER AMENDMENT 3/5/01 : All patient require maintain HAART regimen approve protocol chair . ] Zidovudine ( ZDV ) , lamivudine ( 3TC ) , stavudine ( d4T ) , didanosine ( ddI ) , delavirdine ( DLV ) , ritonavir ( RTV ) , saquinavir soft gel capsule ( SQV sgc ) provide on-study . [ AS PER AMENDMENT 9/19/00 : ZDV , 3TC , 3TC/ZDV combination tablet , d4T , ddI , DLV , RTV , SQV sgc supply protocol 182 week . ] [ AS PER AMENDMENT 3/5/01 : The following antiretroviral medication supply protocol Steps 1 2 : ZDV , 3TC , 3TC/ZDV combination tablet , d4T , ddI , DLV , RTV , SQV sgc . ] Therapy continue 54 week . [ AS PER AMENDMENT 10/6/98 : The initial 54-week trial follow additional 2 year long-term evaluation . Also per amendment , protocol therapy initiate Week 6 . ] [ AS PER AMENDMENT 9/19/00 : The initial 54-week trial follow additional 2.5 year long-term evaluation . ] [ AS PER AMENDMENT 3/5/01 : Step 1 initial 54 week treatment follow 140 week long-term follow-up . Step 2 additional 36 week long-term follow-up . Patients complete final visit Step 2 ( Week 230 ) return clinic 4 week receive last dose study-provided medication complete final evaluation . ] [ AS PER AMENDMENT 10/6/98 : Patients may co-enroll immunology substudy . ] [ AS PER AMENDMENT 6/11/99 : The immunology substudy pilot 3 4 volunteer may proceed feasibility pilot project review . ]</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Delavirdine</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Protocol Chairapproved antiretroviral medication research study treatment HIV complication . Treatment , maintenance , chemoprophylaxis approve medication opportunistic infection . Antibiotics . Recombinant erythropoietin ( rEPO ) granulocyte colonystimulating factor ( GCSF , filgrastim ) . Regularly prescribed medication , antipyretic , analgesic , allergy medication , antidepressant , sleep medication , oral contraceptive ( sole form birth control ) , megestrol acetate , testosterone , medication explicitly exclude . Alternative therapy vitamin , acupuncture , visualization technique . Patients must : HIVpositive status . Completion 48 week study treatment ACTG 315 maintenance regimen ( onstudy ) enrollment study . Signed , inform consent parent legal guardian patient le 18 year age . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Documented suspect pancreatitis hepatitis within 2 week prior study entry . Concurrent Medication : Excluded : Immunomodulators affect immunologic virologic index ( e.g. , systemic corticosteroid , thalidomide , cytokine ) . Ketoconazole , rifampin , rifabutin . Amiodarone , astemizole , bepridil , bupropion , cisapride , clozapine , dihydroergotamine , encainide , ergotamine , flecainide , meperidine , pimozide , piroxicam , propafenone , propoxyphene , quinidine , terfenadine , alprazolam , clorazepate , diazepam , estazolam , flurazepam , midazolam , triazolam , zolpidem , phenytoin , phenobarbital , carbamazepine . [ AS PER AMENDMENT 3/5/01 : Lovastatin simvastatin . Excluded patient pregnant : ddI d4T . ] Avoided : Herbal medication . [ 2 . AS PER AMENDMENT 4/10/00 : Use ddI contraindicate patient serum amylase lipase value 1.5 time ULN ( Upper Limit Normal ) , fast triglyceride 100 mg/dl , history pancreatitis . Use ddI extreme caution clinically indicated patient know risk factor . Refer package insert information . ] Concurrent Treatment : Excluded : Systemic cytotoxic chemotherapy . Prior Medication : Excluded : Any antiretroviral medication zidovudine , lamivudine , ritonavir supply ACTG 315 alternative antiretrovirals approve protocol chair , 48 week prior study entry . Immunomodulatory therapy within 30 day prior study entry . Required : Zidovudine ( 200 mg tid 300 mg bid ) plus lamivudine ( 150 mg bid ) plus ritonavir ( 500 600 mg bid , 300 mg tid ) 48 week ACTG 315 . Active substance alcohol abuse dependence would interfere adherence study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Hypersensitivity , Delayed</keyword>
	<keyword>Follow-Up Studies</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>